By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



39, rue du Bois Chaland

Evry Cedex    91029  France
Phone: 33-1-608-72600 Fax: 33-1-608-61609



Company News
Ipsen (IPN.PA) Preps To Go On Hiring Spree In Europe 7/28/2017 6:14:36 AM
Ipsen (IPN.PA) Delivers Strong Sales Growth Of 18.8%1 In The First Half Of 2017 And Upgrades Its Guidance For Full Year 2017 7/27/2017 7:17:13 AM
Ipsen (IPN.PA): Disclosure Of Transactions In Own Shares Between 17/07/2017 And 21/07/2017 7/25/2017 10:31:10 AM
Ipsen (IPN.PA) Receives Positive CHMP Opinion For Approval Of Xermelo (Telotristat Ethyl), For The Treatment Of Carcinoid Syndrome Diarrhea In Patients Inadequately Controlled By Somatostatin Analogue Therapy 7/21/2017 7:17:29 AM
Lexicon Pharma (LXRX) Collaborator Ipsen (IPN.PA) Receives Positive CHMP Opinion For Xermelo (Telotristat Ethyl) 7/21/2017 6:52:01 AM
Ipsen (IPN.PA): Disclosure Of Transactions In Own Shares Between 10/07/2017 And 14/07/2017 7/18/2017 7:45:34 AM
Ipsen (IPN.PA): Somatuline Autogel 120 Mg Receives Japanese Approval For A New Indication For The Treatment Of Gastro-Entero-Pancreatic Neuroendocrine Tumors 7/5/2017 6:52:50 AM
Ipsen (IPN.PA) Announces Co-Promotion Agreement With Saol Therapeutics To Promote Dysport® (Abobotulinumtoxina) In The United States 6/30/2017 7:36:36 AM
Ipsen (IPN.PA) And Its Partner Exelixis (EXEL) Announce Independent Radiology Committee Review Confirms Results From Phase II CABOSUN Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma 6/20/2017 7:18:03 AM
Ipsen (IPN.PA) Announces FDA Approval Of Dysport (Abobotulinumtoxina) For The Treatment Of Lower Limb Spasticity In Adults 6/16/2017 10:57:30 AM